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Abstract
Genetic testing has grown dramatically in the past decade and is becoming an integral part of 
health care. Genetic nondiscrimination laws have been passed in many states, and the Genetic 
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Information Nondiscrimination Act (GINA) was passed at the federal level in 2008. These laws 
generally protect individuals from discrimination by health insurers or employers based on genetic 
information, including test results. In 2010, Connecticut, Michigan, Ohio, and Oregon added four 
questions to their Behavioral Risk Factor Surveillance System (BRFSS) survey to assess interest 
in genetic testing, awareness of genetic nondiscrimination laws, concern about genetic 
discrimination in determining life insurance eligibility and cost, and perceived importance of 
genetic nondiscrimination laws that address life insurance. Survey results showed that awareness 
of genetic nondiscrimination laws was low (less than 20 % of the adult population), while 
perceived importance of these types of laws was high (over 80 % of respondents rated them as 
very or somewhat important). Over two-thirds of respondents indicated they were very or 
somewhat concerned about life insurance companies using genetic test results to determine life 
insurance coverage and costs. Results indicate a need for more public education to raise awareness 
of protections provided through current genetic nondiscrimination laws. The high rate of concern 
about life insurance discrimination indicates an additional need for continued dialogue regarding 
the extent of legal protections in genetic nondiscrimination laws.
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Opportunities to use genetic information to inform health care decisions have grown 
considerably over the past decade, yet reported barriers to participation in genetic testing 
threaten to diminish the full potential for health impact. Fear of discrimination in insurance 
and employment have been common themes identified in research studies as barriers to 
genetic testing in clinical and research settings (Allain et al. 2012; Iverson et al. 2013), 
despite limited evidence of genetic discrimination in practice (Joly et al. 2013b; Otlowski et 
al. 2012). By early 2008, 32 states had enacted legislation providing varying levels of 
protection from genetic discrimination (National Conference of State Legislatures 2008). 
However, there was no national minimum standard of protection aside from some 
nondiscrimination provisions included in the Health Insurance Portability and 
Accountability Act (HIPAA) of 1996, which apply only to employer-based and 
commercially-issued group health insurance (Health and Human Services [HHS] 2009; 
National Human Genome Research Institute 2012). To address fears of genetic 
discrimination and provide uniform basic protections for genetic information, the United 
States Congress passed the Genetic Information Nondiscrimination Act of 2008, also known 
as GINA, which prohibits health insurers and employers from using genetic information to 
make health insurance coverage or employment decisions (GINA 2008). All entities covered 
by GINA in the United States must meet its minimum requirements, but such entities must 
also comply with any additional state requirements when they are more protective than 
GINA (HHS 2009).
Under GINA, health insurers and employers may not request, require, or purchase genetic 
information about an individual or the individual’s family members. Health insurers and 
health plan administrators cannot use genetic information to determine coverage, adjust 
premiums, or impose preexisting condition exclusions. Employers cannot use genetic 
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information to make decisions regarding hiring, firing, promotion, or other terms of 
employment (GINA 2008; HHS 2009).
GINA defines “genetic information” as an individual’s genetic tests, the genetic tests of that 
individual’s family members, and the manifestation of a genetic disease or disorder in an 
individual’s family members. The definition of “genetic information” includes information 
related to genetic services requested or received by an individual, such as counseling, 
testing, or education, as well as participation in clinical research that includes genetic 
services. “Family member” includes any first- through fourth-degree relatives of the 
individual, and also includes the fetus of a pregnant individual or an embryo held by an 
individual using assisted reproductive technology. GINA defines “genetic test” as an 
analysis of human DNA, RNA, chromosomes, proteins, or metabolites that detects 
genotypes, mutations, or chromosomal changes. The definition of “genetic test” does not 
include “analysis of proteins or metabolites that does not detect genotypes, mutations or 
chromosomal changes” or “analysis directly related to a manifested disease, disorder or 
pathological condition that could be reasonably detected by a health care professional with 
appropriate training and expertise in the field of medicine involved.” (GINA 2008)
Despite the many protections GINA offers, it does have exceptions and limitations. For 
instance, GINA provisions do not apply to life, disability, or long-term care insurance, and 
GINA does not mandate health insurance coverage for any genetic services. Additionally, 
while GINA prohibits health insurers from determining individual eligibility or rates based 
on the manifestation of genetic diseases in an individual’s family members, it does not 
prohibit eligibility or premium rate decisions based on manifestation of a disease or disorder 
of the enrolled individual. Finally, while GINA prohibits health insurance eligibility and 
premium decisions based on genetic information, it does not prohibit the use of genetic test 
information in health insurance reimbursement decisions (GINA 2008; HHS 2009). The 
recent Patient Protection and Affordable Care Act of 2010 (ACA 2010) enhances consumer 
protections in the private health insurance market and complements some of the provisions 
of GINA (U.S. Congressional Research Service. The Genetic Information 
Nondiscrimination Act of 2011). The law prohibits issuers of health insurance from 
discriminating against patients with genetic diseases by refusing coverage because of 
preexisting conditions. The ACA further prohibits the adjustment of premiums for patients 
with genetic diseases.
Many states, including Connecticut, Michigan, Ohio and Oregon, had some legal protections 
in place to prevent genetic discrimination prior to GINA. The legal provisions varied and, in 
many cases, were not as detailed or comprehensive as the provisions in GINA. However, in 
some instances, state law had additional provisions not addressed in GINA. Table 1 
summarizes the genetic non-discrimination laws in each state, which pre-dated GINA, and 
shows the areas where GINA strengthens the states’ legal protections.
Connecticut law, like GINA, prohibits health insurers from determining eligibility and risk 
classification based on genetic information. Connecticut law also prohibits employers from 
requesting or requiring genetic information about an employee or family member, and they 
cannot use that information for hiring, firing, assignment, promotion, or compensation 
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decisions. While GINA only applies to employers with 15 or more employees, Connecticut 
law applies to employers with three or more employees (Connecticut General Statute [CGS] 
46a-60). Connecticut law defines genetic information broadly, as “information about genes, 
gene products or inherited characteristics that may derive from an individual or family 
member” (CGS 38a-816, CGS 46a-60). It does not specifically define “family member”, 
“genetic testing” or “genetic services” and does not specifically protect against misuse of 
family health history, but these are defined through GINA. While Connecticut law does not 
prohibit insurers from requesting or requiring genetic testing as a condition of enrollment, 
this is prohibited under GINA (Table 1).
Michigan law prohibits health insurers from requiring genetic testing before issuing, 
renewing, or continuing coverage (Michigan Compiled Law [MCL] 550.1401), as does 
GINA. It also prohibits health insurers from disclosing if a genetic test has been conducted, 
as well as the results of any test or other genetic information. Employers cannot require 
genetic testing as a condition of employment, or use genetic information to discriminate 
against an employee (MCL 37.1201). Michigan law defines “genetic information” as 
“information about a gene, gene product, or inherited characteristic derived from a genetic 
test”, and “genetic test” is defined as an analysis of human DNA, RNA, chromosomes, 
metabolites and proteins in a clinical setting to detect heritable disease-related genotypes 
and phenotypes (MCL 550.1401). “A genetic test must be generally accepted in the 
scientific and medical communities as being specifically determinative for the presence, 
absence, or mutation of a gene or chromosome in order to qualify under this definition” 
(MCL 550.1401). Like GINA, Michigan does not include routine physical exams or 
analyses of body fluids unless they are specifically conducted to detect gene or chromosome 
presence, absence or mutation. Michigan law does not define “genetic services,” and it does 
not explicitly include family health history or carrier status in the definition of genetic 
information under MCL 550.1401, but these definitions and inclusions are covered under 
GINA. Like GINA, it does include family health history in its protections of employees in 
MCL 37.1201. Michigan requires healthcare providers to obtain written informed consent 
from an individual prior to pre-symptomatic or predictive genetic testing (MCL 333.17020), 
and this is an area where Michigan law is more prescriptive than GINA (Table 1).
Under Ohio law and GINA, health insurers may not require genetic testing as a precondition 
for coverage, and cannot use genetic information to determine eligibility and rates. Like 
GINA, Ohio defines genetic information as associated with disease and includes carrier 
status. Ohio law does not explicitly include family health history (Ohio Revised Code 
[ORC] 1751.65, ORC 3901.491), but this inclusion of family health history is provided 
through GINA. Likewise, Ohio law does not cover employment discrimination related to 
genetic information, but GINA covers this gap (Table 1).
Oregon was the first state in the country with a comprehensive genetic privacy law, enacted 
in 1995. Oregon law prohibits misuse of genetic information in clinical, research, 
employment, and health insurance settings and limits disclosure. Healthcare providers must 
obtain informed consent from an individual prior to any genetic testing (Oregon Revised 
Statute [ORS] 192.535). Oregon law defines genetic information more narrowly than GINA, 
as information obtained from a genetic test about an individual or the individual’s blood 
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relatives, and the law explicitly excludes family history. However, GINA’s broader 
definitions and inclusions supersede Oregon law. Oregon goes beyond GINA by requiring 
individual consent before a covered entity can obtain, retain, or disclose individually 
identifiable genetic information, and allowing an individual to inspect, request correction of, 
and obtain their genetic records (ORS 192.531 to 192.549, ORS 746.135). The Oregon law 
also requires patient notification and the opportunity to opt-out of possible anonymous or 
coded use of genetic information by the covered entity or a third-party (ORS 192.531 to 
192.549). Like GINA, Oregon law prohibits employers from obtaining, seeking to obtain, or 
using genetic information for employment decisions (ORC 659a.303). Unlike GINA and the 
other three states’ laws, ORS 746.135 does cover disability, life and long-term care 
insurance, and statute language refers generally to “any policy of insurance” (ORS 746.135) 
(Table 1).
According to a recent national survey, only 16 % of Americans are aware of any laws that 
protect the privacy of their genetic information (Cogent Research 2010). To explore public 
awareness and perceived importance of genetic non-discrimination laws in Connecticut, 
Michigan, Ohio, and Oregon, survey questions were added to the 2010 Behavioral Risk 
Factor Surveillance System (BRFSS) survey administered by these four states.
Methods
The BRFSS collects information about health conditions, risk behaviors, and healthcare 
access and utilization in the United States using a random-digit-dialed telephone survey of 
the non-institutionalized population aged 18 years or older from each state. Response rates 
in 2010 were 47.5 % for Connecticut, 56.9 % for Michigan, 52.8 % for Ohio, and 39.1 % for 
Oregon (Centers for Disease Control and Prevention 2010). In 2010, Connecticut, Michigan, 
Ohio, and Oregon added four questions to their state BRFSS survey related to genetic testing 
and genetic discrimination (Table 2). These questions were used to assess the public’s 
interest in genetic testing, their awareness of genetic nondiscrimination laws, and their 
perception of laws that prevent the use of genetic information in determining life insurance 
eligibility and costs. Study covariates included the following sociodemographic variables: 
age group, sex, race/ethnicity, education level, and household income category. Interest in 
genetic testing was also included as a covariate (Tables 3 & 4).
Each state analyzed its own data. Oregon used Stata version 13.1 (StataCorp LP, College 
Station, TX), Michigan used SAS-Callable SUDAAN, Release 11.0.0 (Research Triangle 
Institute, Research Triangle Park, NC), Ohio used SAS, Release 9.2 (SAS Institute, Cary, 
NC), and Connecticut used SAS, Release 9.3 (SAS Institute, Cary, NC). Sample data were 
weighted to reflect the demographic characteristics of the adult population in each of the 
states. The unweighted counts of survey question respondents are reported in Tables 2, 3 and 
4. Pearson chi-square tests were used to look for statistically significant variation by 
sociodemographic categories within each state. Confidence intervals were also used to 
determine significant differences between sociodemographic categories in each state, and 
these were also used for cross-state comparisons. Statistical analyses were not adjusted for 
multiple comparisons.
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The human research protection offices at the Centers for Disease Control and Prevention, 
Oregon Public Health Division, Connecticut Department of Public Health, Michigan 
Department of Community Health, and Ohio Department of Health’s Institutional Review 
Board have determined that the BRFSS survey is exempt from institutional review.
Results
In 2010, less than 20 % of adult respondents had heard about genetic nondiscrimination laws 
such as GINA, with awareness ranging from 13.3 % of adult respondents in Michigan to 
19.1 % in Oregon (Tables 2 & 3). Despite any statistically significant variation in awareness 
by sociodemographic characteristics, awareness remained low across all sociodemographic 
groups in all four states. In all four states, there was significant variation in awareness by 
education. College graduates had the highest percentage of awareness of nondiscrimination 
laws in all four states, yet awareness in this group was still less than 26 % (Table 3).
There was statistically significant variation by income in every state except Michigan. In 
Connecticut and Oregon, households with incomes of $75,000 or more per year were 
significantly more likely than those in the lowest income category (less than $25,000 per 
year) to have heard of genetic nondiscrimination laws. For those in the highest income 
category in these three states, awareness ranged from 16.7 % in Ohio to 26.4 % in Oregon 
(Table 3). Most respondents, even in the highest income category, were unaware of genetic 
nondiscrimination laws.
Awareness was low irrespective of age group. Only Connecticut had significant variation in 
awareness of genetic nondiscrimination laws by age, with those ages 45 through 64 years 
having the highest percentage of awareness (19.0 %), significantly higher than both the 18–
44 years age group (13.5 %) and the age 65 years and older age group (14.1 %). None of the 
other states had this distribution of awareness among the three age groups, nor were any of 
the other states’ differences by age significant (Table 3).
No consistent patterns were seen by race or ethnicity among the four states. Two states, 
Connecticut and Ohio, had significant variation of awareness by race and ethnicity, although 
each state had different distributions among the four race categories. In Connecticut, non-
Hispanic whites were significantly more likely to be aware of genetic nondiscrimination 
than non-Hispanic blacks (16.2 % versus 8.0 %). In Ohio, non-Hispanic blacks had the 
highest percentage of respondents reporting awareness of these laws, and the percentage of 
blacks was significantly higher than the percentage of Hispanics (18.2 % versus 7.6 %). 
Non-Hispanic blacks also had the highest percentage of awareness in Michigan, but there 
was no significant difference between this and the other race categories in Michigan.
There was no significant variation in awareness based on respondent interest in having a 
genetic test for any of the four states.
Irrespective of the state they lived in, most respondents were either somewhat or very 
concerned that life insurance companies might use genetic test results to determine coverage 
and costs, ranging from 66.7 % in Ohio to 76.6 % in Michigan (Table 2). An even greater 
percentage of respondents believed it was somewhat or very important to have laws that 
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prevent genetic test results from being used to determine life insurance coverage and costs, 
ranging from 81.9 % in Ohio to 84.8 % in Connecticut and Michigan (Tables 2 & 4).
For all four states, the percentage of respondents who felt it was somewhat or very important 
to have these laws was significantly higher for those under age 65 years compared with 
those over age 65 years. In addition, higher percentages of females than males viewed life 
insurance nondiscrimination laws as somewhat or very important (Table 4).
Perceived importance of life insurance nondiscrimination laws varied significantly by level 
of education in three of the four states (Connecticut, Ohio, and Oregon). In these three 
states, a significantly higher percentage of college graduates ranked these laws as somewhat 
or very important compared to those with high school education or less. The percentage of 
college graduates in these three states rating life insurance nondiscrimination laws as 
somewhat or very important ranged from 86.5 % in Ohio to 88.1 % in Connecticut; among 
those with a high school education or less, the percentage ranged from 76.3 % in Ohio to 
81.8 % in Connecticut.
There was also significant variation by income level in perceived importance of these laws 
in three of the four states. In Connecticut, Michigan, and Ohio, a significantly higher 
percentage of respondents in households earning $50,000 or more per year felt that life 
insurance genetic discrimination laws were somewhat or very important compared to those 
in the lowest income category (less than $25,000 per year). In these three states, the percent 
of respondents in the highest income category who felt these laws were at least somewhat 
important ranged from 85.5 % in Ohio to 88.4 % in Connecticut, while the percent of 
respondents in the lowest income category ranged from 73.8 % in Connecticut to 78.7 % in 
Michigan.
Finally, perceived importance of laws preventing genetic discrimination in life insurance 
varied significantly by the respondents’ interest in having a genetic test to determine their 
disease risk in the future. A significantly higher percentage of those who were somewhat or 
very interested in having a genetic test viewed these laws as important (89.1 % in Michigan, 
90.4 % in the other three states) compared to those less interested in having a genetic test 
(ranging from 76.5 % in Ohio to 80.2 % in Michigan). Despite this difference, legal 
protections for life insurance were important to a majority of respondents in both interest 
categories.
Discussion
Evidence-based guidelines supporting the use of genetic testing in defined clinical settings 
are increasingly becoming available (Clyne et al. 2014). Practice guidelines are in place to 
guide medical professionals in referring patients to certified genetic counselors and other 
genetic specialists who can help patients make informed testing decisions, interpret test 
results, and share information about state and federal genetic nondiscrimination laws. 
Indeed, recent studies suggest a major shift in genetics specialists’ perspectives on genetic 
discrimination and clinical practices reflecting their general awareness of existing legislative 
protections (Matloff et al. 2013; Huizenga et al. 2010); whereas Laedtke et al. (2012) found 
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that family physician awareness and knowledge of GINA was limited more than a year after 
its passage, with fewer than half reporting awareness of GINA. Genetic counseling and 
testing could lead to life-saving treatments for people who meet increased risk guidelines, 
yet concern about genetic discrimination could be a barrier in some instances (Allain et al. 
2012). While state and federal laws are in place to provide protection against discrimination, 
the 2010 BRFSS found that over 80 % of respondents were unaware of these genetic 
nondiscrimination laws. In all four states, awareness levels were even lower among those 
with less education; and for three out of four states, lower incomes were also associated with 
lower awareness.
Our results are similar to the results of another survey where 85 % of genetic counseling 
clients were unaware of GINA (Parmarti 2011). In a different survey of people with 
Huntington’s disease, their family members, and caregivers, conducted during an 
overlapping period to our study (July 2009–June 2010), greater awareness was found among 
this group (41.2 %); however, less than half of those aware could correctly identify GINA’s 
provisions (Dorsey et al. 2013), suggesting that we might expect far fewer people in our 
study than reflected by reported awareness to understand the protections of GINA. A survey 
of individuals at risk for or affected by hereditary breast and ovarian cancer by Allain et al. 
(2012), which was also conducted in a period overlapping our study (August 2009–
December 2010), found that 52.3 % of respondents were worried about life insurance 
discrimination when they first considered genetic testing, and 54.3 % of respondents who 
had genetic testing were unaware of GINA prior to the survey. Again, awareness is higher 
among this selected group as compared to the current population-based study, but concern 
about genetic discrimination in life insurance is somewhat lower.
A significantly higher percentage of respondents in Oregon reported awareness of genetic 
nondiscrimination laws than in any of the other three states. One possible reason for this 
may be that Oregon’s genetic nondiscrimination law was one of the first in the nation, first 
enacted in 1995 (ORS 192.531 to 192.549). Similar differences were found by Kolor et al. 
(2012) when comparing the percentage of adults aware of direct-to-consumer personal 
genomic tests in Oregon, Connecticut, and Michigan: 29.1 %, 22.9 %, and 15.8 %, 
respectively.
A 2012 survey found that 13 U.S. states regulate genetic information in life insurance 
(Disability Rights Legal and Cancer Legal Resource Center 2012a, b). With the exception of 
Oregon law, GINA and the other three states’ genetic nondiscrimination laws do not have 
provisions for discrimination in life, long-term care, or disability insurance. Most 
respondents from all states were either somewhat or very concerned that life insurance 
companies might use genetic test results to determine coverage and costs, ranging from 66.7 
% in Ohio to 76.6 % in Michigan. Moreover, the majority of respondents in all four states 
(81.9 %–84.8 %) perceived legal protections from genetic discrimination in life insurance as 
very or somewhat important. Respondents who were female, less than 65 years old, and 
somewhat or very interested in receiving a genetic test had the highest percentages reporting 
that these laws are at least somewhat important. Because older adults either already own life 
insurance policies or find it too expensive to buy, they could perceive life insurance 
nondiscrimination laws as less important than younger adults. In three of the four states, 
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high household income and higher education were also associated with higher perceived 
importance. However, despite these demographic differences, a majority of respondents in 
all groups, even those with the lowest percentages, believed that life insurance genetic 
nondiscrimination was somewhat or very important. No demographic category in any state 
had less than 69 % of respondents viewing these legal protections as somewhat or very 
important.
Notably, significant differences in perceived importance of life insurance non-discrimination 
laws were not observed in the current study across the racial and ethnic groups examined. 
Previous studies have found disparities in use of genetic tests and participation in genetic 
research in certain racial and ethnic groups, and reported barriers include fear of 
discrimination (Simon and Petrucelli 2009; Sheppard et al. 2013; Nwulia et al. 2011). Our 
findings were mixed in regard to awareness of nondiscrimination laws. In Ohio, non-
Hispanic black respondents had the highest awareness, and the percentage was significantly 
higher than the percentage for Hispanic respondents. In Connecticut, non-Hispanic black 
respondents had the lowest awareness, significantly lower than the percentage for non-
Hispanic white respondents. In Michigan, non-Hispanic black respondents reported the 
highest level of awareness, but the percentage was not statistically different from the other 
groups.
The percentage of respondents who were somewhat or very interested in receiving a genetic 
test ranged from 39.5 % in Ohio to 52.4 % in Michigan. Many of these people may have 
been uninterested for reasons other than worry about genetic discrimination, but over three-
fourths of those not interested in genetic testing still viewed nondiscrimination laws as 
important. Concern over genetic discrimination, whether it is in health insurance, 
employment, life insurance, or other arenas, could impact health care decisions and health 
outcomes.
Limitations of this study include differences in the sociodemographic characteristics of the 
populations in each state, as well as differences in state survey methodology. Additionally, 
the survey utilized residential landline phone numbers, so respondents without access to a 
working residential landline telephone were not included. The study did not include 
evaluation of the health literacy and numeracy of our survey population. The data collected 
are based on self-reported information, which may be inaccurate if respondents 
misinterpreted the questions. Lastly, the study assessed awareness of GINA, but did not 
evaluate knowledge of the specific protections and limitations of GINA.
Despite these limitations, the results indicate that more policies, processes, and education are 
needed to raise awareness of protections in place for genetic information in the employment, 
research, healthcare, and health insurance arenas. GINA and other state genetic 
nondiscrimination laws have yet to calm anxiety over genetic discrimination in the U.S., as 
most respondents were unaware of genetic nondis-crimination laws and had high levels of 
concern over life insurance genetic discrimination. Recent studies suggest that concerns 
regarding genetic discrimination in health insurance and employment persist in the post-
GINA era (Shostak et al. 2011; Laedtke et al. 2012; Bernhardt et al. 2011). This suggests a 
continued need for educational efforts, although there is some evidence indicating those 
Parkman et al. Page 9













concerns are waning among patients and healthcare providers (Ready et al. 2011; Matloff et 
al. 2013; Huizenga et al. 2010).
Building awareness of the protections offered by these laws may encourage more people to 
undergo appropriate and potentially life-saving genetic counseling and testing. These efforts 
may be particularly important for those with lower levels of formal education and lower 
incomes, as these groups are even less aware of genetic discrimination legal protections than 
the general public and may therefore be less likely to get appropriate genetic counseling or 
testing. There is a continued need for public health and genetic specialists to develop new 
methods for reaching out to populations and individuals with less formal education and 
lower incomes, as they may not have access to the same communication devices and 
networks utilized by those with higher levels of education and income.
The high rate of concern about life insurance discrimination and the high rate of perceived 
importance of laws protecting against life insurance discrimination also point to the need for 
continued dialogue about legal protections in this and other insurance areas. A 
multidisciplinary group convened in 2012 examined whether predictive risk assessment 
based on genomic data should be used for life insurance underwriting (Joly et al. 2013a). In 
their action items, the group acknowledges that “there is at present insufficient benefit to 
warrant the addition of predictive genomic data to actuarial risk stratification models;” 
however, they also encouraged research by insurance companies “on ways to include 
genomic data to their models and the implication for customer’s insurability,” and propose 
actions that insurers and others could take to “alleviate concerns over the use of genomic 
information in life insurance.” The group also supported explicit policies and international 
consensus against requesting genomic research results from life insurance applicants.
Recent reviews of genetic discrimination in general, and in life insurance specifically, 
concluded that the available evidence clearly documents examples of individual cases of 
genetic discrimination (Joly et al. 2013b; Otlowski et al. 2012; Barlow-Stewart et al. 2009). 
However, Joly et al. (2013b) concluded that the evidence for genetic discrimination in life 
insurance has important limitations that make it difficult to justify policy action on its own, 
highlighting the importance of additional factors as considerations in policymaking, such as 
concerns about potential genetic discrimination in life insurance among patients, research 
participants, healthcare providers, and the general public, as barriers to patient care and 
research (Ader et al. 2009; Haga et al. 2011).
We found that 39.5 % to 52.4 % of respondents were interested in having a genetic test that 
could tell them about their risk of having a genetic disease. Despite this moderate level of 
interest, previous studies have shown that few people have used genetic testing services, 
even among those who meet evidence-based genetic testing guidelines (Quillin et al. 2014; 
Levy et al. 2009). This limited real-world experience with genetic testing, coupled with 
respondents’ low awareness of genetic discrimination laws, may reflect a concern with 
genetic discrimination that is presently largely rhetorical for most respondents. As genetic 
testing technology advances and becomes more accessible to a larger portion of the 
population, people may become more personally concerned with the possibility of genetic 
discrimination. Genetic specialists and privacy lawyers can encourage dialogue and 
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awareness of the scope and limitations of our existing legal protections now, rather than 
simply reacting to problems as they arise in the future, which may help ensure a more 
rational policy landscape in a rapidly changing field.
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Table 2
Genetic testing questions from 2010 BRFSS and percent responding “yes” or “very/somewhat”
Connecticut Michigan Ohio Oregon
A genetic test looks at a person’s blood or saliva to find 
differences in genes that might cause disease in the future. How 
interested are you in having a genetic test that could tell you 









How concerned are you that life insurance companies might use 










How important do you think it is to have laws that prevent 










Have you heard about laws that prevent genetic test results from 
being used to determine health insurance coverage and costs? 
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Table 3
Percent aware of genetic nondiscrimination laws, 2010 BRFSS
Connecticut n=6,226
% (95 % CI)
Michigan n=2,713
% (95 % CI)
Ohio n=5,988
% (95 % CI)
Oregon n=2,294
% (95 % CI)
Total 15.6 (14.2–17.0) 13.3 (11.6–15.2) 14.5 (13.2–15.7) 19.1 (17.0–21.3)
Age group p=0.0005 p=0.3691 p=0.0791 p=0.2055
 18–44 13.5 (11.0–16.0) 12.0 (9.2–15.4) 13.1 (11.0–15.3) 20.7 (16.9–25.1)
 45–64 19.0 (16.9–21.0) 14.8 (12.5–17.4) 15.5 (13.7–17.2) 18.4 (15.9–21.3)
 65+ 14.1 (12.3–16.0) 14.8 (11.6–16.8) 16.2 (14.1–18.2) 16.2 (13.7–19.2)
Gender p=0.0352 p=0.5404 p=0.6592 p=0.0778
 Male 17.1 (14.8–19.5) 13.9 (11.4–16.7) 14.8 (12.8–16.8) 21.0 (17.7–24.8)
 Female 14.1 (12.5–15.7) 12.8 (10.6–15.3) 14.2 (12.7–15.7) 17.2 (14.7–19.9)
Race and ethnicity p=0.0476 p=0.5182 p=0.0132 p=0.3645
 White non-Hispanic 16.2 (14.6–17.8) 13.0 (11.2–15.1) 14.2 (12.9–15.5) 19.4 (17.1–21.9)
 Black non-Hispanic 8.0 (4.5–11.5) 17.0 (12.1–23.3) 18.2 (13.5–22.8) b
 Hispanic 12.7 (8.0–17.5) b 7.6 (1.8–13.4) b
 Othera 16.7 (10.0–23.4) 10.7 (5.5–19.6) 15.2 (8.7–21.6) 21.4 (15.1–29.4)
Education p<0.0001 p<0.0001 p=0.0001 p<0.0001
 High school or less 10.0 (8.0–12.1) 8.0 (6.2–10.4) 11.6 (9.8–13.3) 11.0 (8.1–14.9)
 Some college 12.2 (9.8–14.7) 14.9 (11.7–18.7) 14.0 (11.7–16.4) 19.7 (15.9–24.1)
 College graduate 20.7 (18.4–23.1) 17.1 (14.1–20.7) 18.0 (15.7–20.3) 25.4 (21.8–29.2)
Household income p<0.0001 p=0.4249 p=0.0249 p=0.0004
 <$25,000 9.4 (6.9–11.8) 15.3 (11.8–19.7) 13.9 (11.4–16.3) 15.7 (12.0–20.2)
 $25,000–$49,999 13.5 (10.6–16.4) 11.4 (8.6–14.8) 15.2 (12.5–17.9) 14.8 (11.4–19.2)
 $50,000–$74,999 16.0 (12.4–20.0) 13.6 (9.5–19.3) 12.7 (9.8–15.6) 21.5 (16.4–27.7)
 $75,000+ 19.3 (16.8–21.7) 14.2 (11.1–18.0) 16.7 (14.0–19.3) 26.4 (21.9–31.4)
Interest in genetic testing p=0.2218 p=0.0658 p=0.7367 p=0.1780
 Very/somewhat interested 16.6 (14.3–18.9) 14.9 (12.5–17.6) 14.2 (12.2–16.1) 20.6 (17.5–24.1)
 Not very/not at all interested 14.8 (13.1–16.5) 11.6 (9.4–14.2) 14.6 (13.0–16.2) 17.6 (14.9–20.7)
a
Includes respondents with other or unknown race or ethnicity, and respondents identifying as two or more races
b
Insufficient number of respondents, percentage not calculated
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Table 4
Percent that view laws preventing genetic tests results from being used to determine life insurance coverage 
and costs as somewhat or very important, 2010 BRFSS
Connecticut n=6,109
% (95 % CI)
Michigan n=2,691
% (95 % CI)
Ohio n=5,807
% (95 % CI)
Oregon n=2,241
% (95 % CI)
Total 84.8 (83.4–86.2) 84.8 (82.8–86.6) 81.9 (80.5–83.3) 83.7 (81.6–85.6)
Age group p<0.0001 p<0.0001 p<0.0001 p<0.0001
 18–44 85.8 (83.2–88.3) 86.4 (82.6–89.4) 84.7 (82.2–87.2) 87.6 (83.5–90.8)
 45–64 88.2 (86.6–89.8) 87.8 (85.3–90.0) 84.1 (82.3–85.9) 85.6 (82.9–88.0)
 65+ 76.0 (73.7–78.3) 74.4 (71.0–77.5) 69.9 (67.2–72.5) 69.4 (65.8–72.8)
Gender p=0.0022 p=0.0005 p=0.0027 p=0.0280
 Male 82.6 (80.3–84.9) 81.3 (77.8–84.3) 79.7 (77.3–82.1) 81.4 (77.9–84.5)
 Female 86.8 (85.2–88.4) 88.1 (85.9–89.9) 84.0 (82.4–85.5) 85.9 (83.3–88.1)
Race and ethnicity p=0.8438 p=0.5091 p=0.3077 p=0.4498
 White non-Hispanic 85.1 (83.6–86.6) 84.5 (82.2–86.5) 81.6 (80.0–83.1) 84.5 (82.3–86.5)
 Black non-Hispanic 82.9 (76.6–89.3) 85.1 (80.0–89.1) 86.2 (82.4–89.9) 81.9 (39.1–96.9)
 Hispanic 84.7 (79.6–89.8) b 84.2 (74.9–93.5) 82.5 (67.7–91.4)
 Othera 82.9 (76.7–89.2) 90.2 (81.3–95.1) 82.1 (74.1–90.1) 78.2 (70.1–84.6)
Education p<0.0001 p=0.4373 p=0.0001 p=0.0134
 High school or less 80.4 (77.6–83.2) 83.0 (79.4–86.1) 76.3 (73.8–78.8) 81.8 (77.9–85.1)
 Some college 83.8 (80.9–86.6) 85.6 (82.0–88.6) 83.7 (80.9–86.4) 80.9 (76.3–84.9)
 College graduate 88.1 (86.3–90.0) 85.8 (82.2–88.7) 86.5 (84.4–88.5) 87.6 (84.6–90.0)
Household income p<0.0001 p=0.0132 p=0.0001 p=0.1085
 <$25,000 73.8 (68.8–78.7) 78.7 (73.6–83.1) 76.2 (72.8–79.5) 83.3 (78.8–87.0)
 $25,000–$49,999 80.9 (77.4–84.4) 87.3 (83.5–90.3) 82.5 (79.8–85.2) 81.7 (77.0–85.6)
 $50,000–$74,999 88.3 (85.3–91.3) 87.1 (82.5–90.7) 87.8 (84.8–90.7) 86.3 (81.0–90.3)
 $75,000+ 88.4 (86.4–90.4) 87.8 (84.0–90.8) 85.5 (82.9–88.2) 87.8 (83.9–90.9)
Interest in genetic testing p<0.0001 p<0.0001 p=0.0001 p<0.0001
 Very/somewhat interested 90.4 (88.5–92.2) 89.1 (86.4–91.3) 90.4 (88.5–92.2) 90.4 (87.7–92.5)
 Not very/not at all interested 79.9 (77.9–81.9) 80.2 (77.1–83.0) 76.5 (74.6–78.5) 77.2 (73.9–80.2)
a
Includes respondents with other or unknown race or ethnicity, and respondents identifying as two or more races
b
Insufficient number of respondents, percentage not calculated
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